Thanh Nguyen, DO
Interventional Cardiology · Glendale, CANPI 1134165194
Payments from drug & device makers
Across 569 payments — averaging $52.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- Medtronic$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Penumbra, Inc.$2K
- Abiomed$1K
- Boston Scientific$891
- plus $3K from 20 others
What the payments were for
- Travel & lodging$2,3618%
- Food & beverage$27,75792%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 219 | $14,652 |
| Medtronic(2 entities) | 161 | $6,909 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 58 | $2,107 |
| Penumbra, Inc. | 12 | $1,733 |
| Abiomed | 30 | $1,241 |
| Boston Scientific | 17 | $891 |
| Cvrx, Inc. | 8 | $497 |
| Johnson & Johnson | 15 | $304 |
| Actelion Pharmaceuticals US, Inc. | 2 | $260 |
| Amgen | 9 | $201 |
| Edwards Lifesciences | 1 | $196 |
| AstraZeneca | 5 | $196 |
| Novartis | 8 | $186 |
| Cardiva Medical, Inc. | 4 | $146 |
| Biotronik Inc. | 2 | $142 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $83 |
| Biosense Webster, Inc. | 1 | $63 |
| Cardiovascular Systems Inc. | 4 | $59 |
| Heartflow, Inc. | 2 | $56 |
| Pfizer | 2 | $50 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $41 |
| Irhythm Technologies, Inc. | 1 | $39 |
| Boehringer Ingelheim | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 1 | $25 |
| Shockwave Medical, Inc | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$3,310
- Micra$2,340
- Indigo System$1,483
- DRAGONFLY OPSTAR$1,225
- AVEIR$978
- PRESSUREWIRE$764
- Dragonfly OCT$756
- GALLANT$619
- LifeVest$566
- QUADRA ASSURA$482
- XIENCE SKYPOINT$442
- Quadra Assura CRT Defibrillator$436
- Barostim Neo System$357
- COBALT DR MRI SURESCAN$319
- Azure$316
- AZURE XT DR MRI SURESCAN$315
- Merlin Connectivity and Remote$304
- Impella$292
- Indigo$291
- Reveal LINQ$291
How this compares
$30,153 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 228 | $234,479 |
| EliquisApixaban | 185 | $223,200 |
| OzempicSemaglutide | 101 | $136,557 |
| Repatha SureclickEvolocumab | 144 | $123,756 |
| EntrestoSacubitril/Valsartan | 35 | $52,322 |
| JanuviaSitagliptin Phosphate | 25 | $28,421 |
| MounjaroTirzepatide | 19 | $19,448 |
| BrilintaTicagrelor | 18 | $14,678 |
| TrulicityDulaglutide | 15 | $13,969 |
| Praluent PenAlirocumab | 13 | $9,590 |
| Atorvastatin Calcium | 923 | $8,679 |
| Flecainide Acetate | 133 | $7,945 |
| Repatha SyringeEvolocumab | 12 | $6,840 |
| ClopidogrelClopidogrel Bisulfate | 354 | $4,766 |
| Losartan Potassium | 412 | $3,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $304 | $234,479228 claims |
| PfizerEliquis | $50 | $223,200185 claims |
| NovartisEntresto | $186 | $52,32235 claims |
| AstraZenecaBrilinta | $196 | $14,67818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Glendale
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.